Hepatocyte-intrinsic type I interferon signaling reprograms metabolism and reveals a novel compensatory mechanism of the tryptophan-kynurenine pathway in viral hepatitis.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
10 2020
Historique:
received: 29 04 2020
accepted: 10 09 2020
revised: 22 10 2020
pubmed: 13 10 2020
medline: 5 1 2021
entrez: 12 10 2020
Statut: epublish

Résumé

The liver is a central regulator of metabolic homeostasis and serum metabolite levels. Hepatocytes are the functional units of the liver parenchyma and not only responsible for turnover of biomolecules but also act as central immune signaling platforms. Hepatotropic viruses infect liver tissue, resulting in inflammatory responses, tissue damage and hepatitis. Combining well-established in vitro and in vivo model systems with transcriptomic analyses, we show that type I interferon signaling initiates a robust antiviral immune response in hepatocytes. Strikingly, we also identify IFN-I as both, sufficient and necessary, to induce wide-spread metabolic reprogramming in hepatocytes. IFN-I specifically rewired tryptophan metabolism and induced hepatic tryptophan oxidation to kynurenine via Tdo2, correlating with altered concentrations of serum metabolites upon viral infection. Infected Tdo2-deficient animals displayed elevated serum levels of tryptophan and, unexpectedly, also vast increases in the downstream immune-suppressive metabolite kynurenine. Thus, Tdo2-deficiency did not result in altered serum homeostasis of the tryptophan to kynurenine ratio during infection, which seemed to be independent of hepatocyte-intrinsic compensation via the IDO-axis. These data highlight that inflammation-induced reprogramming of systemic tryptophan metabolism is tightly regulated in viral hepatitis.

Identifiants

pubmed: 33045014
doi: 10.1371/journal.ppat.1008973
pii: PPATHOGENS-D-20-00873
pmc: PMC7580883
doi:

Substances chimiques

Antiviral Agents 0
Ifnar1 protein, mouse 0
Interferon Regulatory Factor-7 0
Irf7 protein, mouse 0
STAT1 Transcription Factor 0
Stat1 protein, mouse 0
Receptor, Interferon alpha-beta 156986-95-7
Kynurenine 343-65-7
Tryptophan 8DUH1N11BX
Tryptophan Oxygenase EC 1.13.11.11

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008973

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Cell. 1996 Feb 9;84(3):443-50
pubmed: 8608598
Cell Rep. 2015 Nov 10;13(6):1081-1089
pubmed: 26526991
Nat Immunol. 2013 Oct;14(10):996-1006
pubmed: 24048121
J Inherit Metab Dis. 1991;14(4):407-20
pubmed: 1749209
Immunity. 2019 Dec 17;51(6):1074-1087.e9
pubmed: 31784108
Hepatology. 2006 Nov;44(5):1182-90
pubmed: 17058232
Immunity. 2015 Nov 17;43(5):974-86
pubmed: 26588782
Cell. 2017 May 4;169(4):570-586
pubmed: 28475890
EMBO Mol Med. 2017 Jun;9(6):816-834
pubmed: 28360091
Immunol Rev. 2010 Jul;236:243-64
pubmed: 20636821
Genesis. 2004 Jul;39(3):167-72
pubmed: 15282742
Nature. 2006 Dec 14;444(7121):860-7
pubmed: 17167474
Int J Tryptophan Res. 2019 Aug 21;12:1178646919868978
pubmed: 31488951
Cell. 2016 Oct 20;167(3):829-842.e13
pubmed: 27745970
Curr Biol. 2017 Nov 6;27(21):R1147-R1151
pubmed: 29112863
Nat Immunol. 2016 Jun;17(6):687-94
pubmed: 27089381
Cell. 2009 Jul 10;138(1):30-50
pubmed: 19596234
Cancer Res. 2015 Nov 1;75(21):4651-64
pubmed: 26363006
Bioinformatics. 2009 Apr 15;25(8):1091-3
pubmed: 19237447
Clin Chem. 1998 Apr;44(4):858-62
pubmed: 9554499
J Immunol. 2012 Apr 15;188(8):3980-7
pubmed: 22422885
Cell. 2015 Apr 23;161(3):486-500
pubmed: 25892224
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Int J Tryptophan Res. 2017 Oct 09;10:1178646917735098
pubmed: 29051706
J Neurochem. 2016 Mar;136(6):1142-1154
pubmed: 26708701
Trends Immunol. 2013 Mar;34(3):137-43
pubmed: 23103127
Immunity. 2013 Apr 18;38(4):633-43
pubmed: 23601682
Front Immunol. 2014 Nov 20;5:585
pubmed: 25477879
J Exp Med. 1986 Oct 1;164(4):1075-92
pubmed: 3489805
Int J Infect Dis. 2020 Feb;91:162-168
pubmed: 31821895
J Immunol. 2016 Jan 1;196(1):17-21
pubmed: 26685314
Blood. 2010 Apr 29;115(17):3520-30
pubmed: 20197554
Oncotarget. 2016 May 10;7(19):27584-98
pubmed: 27050278
Nat Rev Neurosci. 2012 Jul;13(7):465-77
pubmed: 22678511
J Exp Med. 1999 May 17;189(10):1555-64
pubmed: 10330434
Front Immunol. 2015 Jan 12;5:673
pubmed: 25628622
J Virol. 2003 Apr;77(8):4911-27
pubmed: 12663797
Cell. 2020 Sep 3;182(5):1252-1270.e34
pubmed: 32818467
Curr Top Microbiol Immunol. 2002;263:1-5
pubmed: 11987811
Cell Mol Immunol. 2016 May;13(3):301-15
pubmed: 26685902
Nat Rev Immunol. 2016 Sep;16(9):553-65
pubmed: 27396447
Cell Rep. 2016 Nov 22;17(9):2247-2258
pubmed: 27880901
Immunity. 2016 Jun 21;44(6):1325-36
pubmed: 27332732
Cell. 2015 Feb 26;160(5):816-827
pubmed: 25723161
Mol Cancer Res. 2019 Jan;17(1):131-139
pubmed: 30143553
Exp Ther Med. 2015 Mar;9(3):901-904
pubmed: 25667650
Nat Rev Immunol. 2015 Feb;15(2):87-103
pubmed: 25614319
Immunol Rev. 2012 Sep;249(1):135-57
pubmed: 22889220
Nat Immunol. 2016 Feb;17(2):132-9
pubmed: 26784254
Nat Rev Immunol. 2014 Jan;14(1):36-49
pubmed: 24362405
Cell. 2015 Dec 17;163(7):1716-29
pubmed: 26686653
Nat Rev Immunol. 2004 Oct;4(10):762-74
pubmed: 15459668
PLoS Biol. 2014 Jan;12(1):e1001759
pubmed: 24409099
J Gen Virol. 2007 Feb;88(Pt 2):592-603
pubmed: 17251578
Immunity. 2020 Sep 15;53(3):496-509
pubmed: 32937151
J Exp Med. 2002 Aug 19;196(4):447-57
pubmed: 12186837
Nat Med. 2016 Jun;22(6):586-97
pubmed: 27158906
Nature. 2005 Apr 7;434(7034):772-7
pubmed: 15800576
Nature. 2014 Jul 10;511(7508):184-90
pubmed: 24930766
Nat Rev Immunol. 2005 Mar;5(3):215-29
pubmed: 15738952
Nat Rev Immunol. 2012 Feb 24;12(3):201-13
pubmed: 22362353
Mol Brain. 2009 Mar 27;2:8
pubmed: 19323847
Sci Rep. 2017 Jan 24;7:41271
pubmed: 28117398
Brain Behav Immun. 2015 Aug;48:274-86
pubmed: 25900439
Immunol Cell Biol. 2003 Aug;81(4):247-65
pubmed: 12848846
Cell. 2020 Jul 9;182(1):59-72.e15
pubmed: 32492406
Blood. 2006 Nov 15;108(10):3253-61
pubmed: 16868248
J Biol Chem. 2017 Jan 6;292(1):15-30
pubmed: 27903651
Nat Rev Immunol. 2019 Mar;19(3):184-197
pubmed: 30718831
Annu Rev Immunol. 2014;32:513-45
pubmed: 24555472
Front Immunol. 2014 Oct 09;5:485
pubmed: 25346733
Immunity. 2015 Sep 15;43(3):421-34
pubmed: 26377896

Auteurs

Alexander Lercher (A)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse, Vienna, Austria.

Alexandra M Popa (AM)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse, Vienna, Austria.

Csilla Viczenczova (C)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse, Vienna, Austria.

Lindsay Kosack (L)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse, Vienna, Austria.

Kristaps Klavins (K)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse, Vienna, Austria.

Benedikt Agerer (B)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse, Vienna, Austria.

Christiane A Opitz (CA)

DKTK Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Neurology Clinic and National Center for Tumor Diseases, University Hospital of Heidelberg, Heidelberg, Germany.

Tobias V Lanz (TV)

Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.
Department of Neurology, University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany.

Michael Platten (M)

Department of Neurology, University of Heidelberg, Medical Faculty Mannheim, Mannheim, Germany.
DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Andreas Bergthaler (A)

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH